Sooo... if I may be so bold as to post something a
Post# of 36537
Does no one have thoughts on the separation between NGIO and GNBT on the Wednesday call? Why are the NGIO/vaccine topics two of the main bullets on the Generex call?
I missed the last NGIO call, but my understanding was there was no GNBT content allowed to be addressed in the Qs.
IMO, we really do need to separate the two entities, particularly if potential investors are listening to these calls. It’s going to confuse everyone as to what belongs in which bucket.